Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy
Status:
Completed
Trial end date:
2020-01-06
Target enrollment:
Participant gender:
Summary
The overall hospitalizations for a diagnosis of angioedema doubled from the year 2000 to
2009. Although some of the cases represented hereditary angioedema or ace-inhibitor induced
angioedema, the majority of episodes were idiopathic. Idiopathic Angioedema (IAE) can be
life- threatening especially when affecting tissues within the respiratory tract. No clear
guidelines exist for management of this important condition for clinicians. Current therapies
typically include avoidance of potential triggers and use of medications either for
prophylaxis or for acute events, such as antihistamines, corticosteroids, and epinephrine.
There remains a critical need for therapeutic options to provide more effective prophylaxis.